The commencement of NXC-201 Engineering Batches at Nexcella's U.S. manufacturing site is a crucial step in transferring the existing CAR-T GMP manufacturing process to the U.S. This will support the planned expansion of the ongoing NEXICART-1 clinical trial to the United States, potentially leading to increased demand for Immix Biopharma's products and services, and ultimately having a positive impact on the company's stock price in the short term.